Rank
69
Merck
An employee monitors Euthyrox hypothyroid treatment tablets as they pass through a blister pack packaging machine inside Merck KGaA's pharmaceutical laboratories at the company's headquarters in Darmstadt, Germany, on Thursday, Nov. 3, 2016. Merck and Idemitsu Kosan Co Ltd. today signed an agreement to allow each party to use the other's organic light-emitting diode (OLED) material-related patents in certain areas. Photographer: Martin Leissl/Bloomberg via Getty ImagesMartin Leissl — Bloomberg via Getty Images
- Previous Rank72
- Revenues ($M)39807
- Revenue Percent Change0.8
- Profits ($M)3920
- Profits Percent Change-11.8
- Assets ($M)95377
- Employees68000
- Market Value — as of March 31, 2017 ($M)174454
Merck brought in $39.8 billion in 2016 global sales. The U.S. drug giant's wide-ranging portfolio was crucial to that haul but the company's next-generation cancer immunotherapy treatment, Keytruda, is what really set it apart last year. The therapy bested rival Bristol-Myers Squibb's competing Opdivo in the critical lung cancer space, according to clinical trial data, making it (and Merck) one of the most formidable players in the latest strike on cancer.
Company Info
| CEO | Kenneth C. Frazier |
| CEO Title | Chairman, President & Chief Executive Officer |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| HQ Location | Kenilworth, NJ |
| Website | www.merck.com |
| Years on Fortune 500 List | 23 |
| Employees | 68,000 |
Key Financials (Last Fiscal Year)
| Revenues ($M) | $39,807 |
| Profits ($M) | $3,920 |
| Assets ($M) | $95,377 |
| Total Stockholder Equity ($M) | $40,088 |
| Market Value — as of March 31, 2017 ($M) | $174,454 |
Profit Ratios
| Profit as % of Revenues | 9.8% |
| Profits as % of Assets | 4.1% |
| Profits as % of Stockholder Equity | 9.8% |
Earnings Per Share (Last Fiscal Year)
| Earnings Per Share ($) | 1 |
| EPS % Change (from 2015) | -9.6% |
| EPS % Change (5 year annual rate) | -6.9% |
| EPS % Change (10 year annual rate) | -3.6% |
Total Return
| Total Return to Investors (2016) | 15.1% |
| Total Return to Investors (5 year, annualized) | 13.2% |
| Total Return to Investors (10 year, annualized) | 7% |